Publications
Print PDF
Policy Reversal: FDA Will No Longer Require Suffixes for Older Biologics
March 7, 2019
Michael Cipriano
Pink Sheet

Axinn partner Chad Landmon was quoted in the Pink Sheet article, "Policy Reversal: FDA Will No Longer Require Suffixes for Older Biologics."

Click here to access the article.

By using the Axinn, Veltrop & Harkrider LLP website with cookies enabled on your browser, you agree to our use of cookies during your browsing experience. Learn more about our privacy policy.